FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162789253> ?p ?o ?g. }

• W3162789253 endingPage "30" @default.
• W3162789253 startingPage "20" @default.
• W3162789253 abstract "TPN672 [7-(2-(4-(benzothiophen-4-yl) piperazin-1-yl)ethyl)quinolin-2(1H)-one maleate] is a novel antipsychotic candidate with high affinity for serotonin and dopamine receptors that is currently in clinical trial for the treatment of psychiatric disorders. In vitro binding study showed that TPN672 exhibited extremely high affinity for serotonin 1A receptor (5-HT1AR) (Ki = 0.23 nM) and 5-HT2AR (Ki = 2.58 nM) as well as moderate affinity for D3R (Ki = 11.55 nM) and D2R (Ki = 17.91 nM). In vitro functional assays demonstrated that TPN672 acted as a potent 5-HT1AR agonist, D2R/D3R partial agonist, and 5-HT2AR antagonist. TPN672 displayed robust antipsychotic efficacy in rodent models (e.g., blocking phencyclidine-induced hyperactivity), significantly better than aripiprazole, and ameliorated negative symptoms and cognitive deficits in the sociability test, dark avoidance response, Morris water maze test, and novel object recognition test. The results of electrophysiological experiments showed that TPN672 might inhibit the excitability of the glutamate system through activating 5-HT1AR in medial prefrontal cortex, thereby improving cognitive and negative symptoms. Moreover, the safety margin (the ratio of minimum catalepsy-inducing dose to minimum effective dose) of TPN672 was about 10-fold, which was superior to aripiprazole. In conclusion, TPN672 is a promising new drug candidate for the treatment of schizophrenia and has been shown to be more effective in attenuating negative symptoms and cognitive deficits while having lower risk of extrapyramidal symptoms and hyperprolactinemia. SIGNIFICANCE STATEMENT: TPN672 is a promising new drug candidate for the treatment of schizophrenia and has been shown to be more effective in attenuating negative symptoms and cognitive deficits while having a lower risk of extrapyramidal symptoms and hyperprolactinemia. A phase I clinical trial is now under way to test its tolerance, pharmacokinetics, and pharmacodynamic effects in human volunteers. Accordingly, the present results will have significant impact on the development of new antischizophrenia drugs." @default.
• W3162789253 created "2021-05-24" @default.
• W3162789253 creator A5008792226 @default.
• W3162789253 creator A5015338788 @default.
• W3162789253 creator A5025190969 @default.
• W3162789253 creator A5034629735 @default.
• W3162789253 creator A5050845568 @default.
• W3162789253 creator A5053942013 @default.
• W3162789253 creator A5066165236 @default.
• W3162789253 creator A5066471162 @default.
• W3162789253 creator A5079594267 @default.
• W3162789253 creator A5081415126 @default.
• W3162789253 date "2021-05-11" @default.
• W3162789253 modified "2023-10-05" @default.
• W3162789253 title "TPN672: A Novel Serotonin-Dopamine Receptor Modulator for the Treatment of Schizophrenia" @default.
• W3162789253 cites W1481581387 @default.
• W3162789253 cites W1968532777 @default.
• W3162789253 cites W1977138162 @default.
• W3162789253 cites W1986782185 @default.
• W3162789253 cites W2011297026 @default.
• W3162789253 cites W2026583759 @default.
• W3162789253 cites W2032187584 @default.
• W3162789253 cites W2034006349 @default.
• W3162789253 cites W2035408447 @default.
• W3162789253 cites W2044997440 @default.
• W3162789253 cites W2048692599 @default.
• W3162789253 cites W2051869406 @default.
• W3162789253 cites W2052765057 @default.
• W3162789253 cites W2054695075 @default.
• W3162789253 cites W2074508780 @default.
• W3162789253 cites W2095213614 @default.
• W3162789253 cites W2098903596 @default.
• W3162789253 cites W2127272758 @default.
• W3162789253 cites W2127339766 @default.
• W3162789253 cites W2129506769 @default.
• W3162789253 cites W2137044087 @default.
• W3162789253 cites W2142137999 @default.
• W3162789253 cites W2142688346 @default.
• W3162789253 cites W2162105640 @default.
• W3162789253 cites W2167223183 @default.
• W3162789253 cites W2168179372 @default.
• W3162789253 cites W2268825926 @default.
• W3162789253 cites W2325615500 @default.
• W3162789253 cites W2336560483 @default.
• W3162789253 cites W2606703275 @default.
• W3162789253 cites W2729684734 @default.
• W3162789253 cites W2898434904 @default.
• W3162789253 cites W2900981431 @default.
• W3162789253 cites W2905833648 @default.
• W3162789253 cites W2954807799 @default.
• W3162789253 cites W2964999518 @default.
• W3162789253 cites W2971367601 @default.
• W3162789253 cites W3015204490 @default.
• W3162789253 cites W4211025465 @default.
• W3162789253 cites W4211145950 @default.
• W3162789253 cites W948132221 @default.
• W3162789253 doi "https://doi.org/10.1124/jpet.120.000414" @default.
• W3162789253 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33975897" @default.
• W3162789253 hasPublicationYear "2021" @default.
• W3162789253 type Work @default.
• W3162789253 sameAs 3162789253 @default.
• W3162789253 citedByCount "3" @default.
• W3162789253 countsByYear W31627892532022 @default.
• W3162789253 countsByYear W31627892532023 @default.
• W3162789253 crossrefType "journal-article" @default.
• W3162789253 hasAuthorship W3162789253A5008792226 @default.
• W3162789253 hasAuthorship W3162789253A5015338788 @default.
• W3162789253 hasAuthorship W3162789253A5025190969 @default.
• W3162789253 hasAuthorship W3162789253A5034629735 @default.
• W3162789253 hasAuthorship W3162789253A5050845568 @default.
• W3162789253 hasAuthorship W3162789253A5053942013 @default.
• W3162789253 hasAuthorship W3162789253A5066165236 @default.
• W3162789253 hasAuthorship W3162789253A5066471162 @default.
• W3162789253 hasAuthorship W3162789253A5079594267 @default.
• W3162789253 hasAuthorship W3162789253A5081415126 @default.
• W3162789253 hasBestOaLocation W31627892531 @default.
• W3162789253 hasConcept C118552586 @default.
• W3162789253 hasConcept C126322002 @default.
• W3162789253 hasConcept C15744967 @default.
• W3162789253 hasConcept C169760540 @default.
• W3162789253 hasConcept C169900460 @default.
• W3162789253 hasConcept C170493617 @default.
• W3162789253 hasConcept C2775864247 @default.
• W3162789253 hasConcept C2776412080 @default.
• W3162789253 hasConcept C2778851735 @default.
• W3162789253 hasConcept C2778938600 @default.
• W3162789253 hasConcept C2780211496 @default.
• W3162789253 hasConcept C2781195155 @default.
• W3162789253 hasConcept C44208683 @default.
• W3162789253 hasConcept C513476851 @default.
• W3162789253 hasConcept C53910766 @default.
• W3162789253 hasConcept C58732023 @default.
• W3162789253 hasConcept C67018056 @default.
• W3162789253 hasConcept C71924100 @default.
• W3162789253 hasConcept C98274493 @default.
• W3162789253 hasConceptScore W3162789253C118552586 @default.
• W3162789253 hasConceptScore W3162789253C126322002 @default.
• W3162789253 hasConceptScore W3162789253C15744967 @default.

• next